Retina Publications

Three-year treatment outcomes of Aflibercept versus Ranibizumab for diabetic macular edema: data from the Fight Retinal Blindness! Registry

Retina

2022 June

12-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry

British Journal of Ophthalmology

2022 June

Incidence, Risk Factors and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor for Retinal Diseases: Data from the Fight Retinal Blindness! Registry

Ophthalmology Retina

, (epub)

2022 May

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion

Eye

, (epub)

2022 May

Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry

Acta Ophthalmologica

2022 May

Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes

Clinical and Experimental Ophthalmology

2022 April

International impact of the COVID-19 pandemic lockdown on intravitreal therapy outcomes: Fight Retinal Blindness registry

Retina

2022 April

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry

Ophthalmology and Therapy

2022 April

Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry

Acta Ophthalmology

, (epub)

2022 March

Characterization of poor visual outcomes of diabetic macular edema: the Fight Retinal Blindness! Project

Ophthalmology Retina

, (epub)

2022 March

Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry

Eye

2022 March

Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration

Retina

, (epub)

2022 February

Email: ssi.ssr@sydney.edu.au
Phone: (+61) 421 787 808

Level 1, South Block
Sydney Eye Hospital
8 Macquarie Street
Sydney NSW 2000

Retina Publications

Three-year treatment outcomes of Aflibercept versus Ranibizumab for diabetic macular edema: data from the Fight Retinal Blindness! Registry

12-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry

Incidence, Risk Factors and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor for Retinal Diseases: Data from the Fight Retinal Blindness! Registry

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion

Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry

Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes

International impact of the COVID-19 pandemic lockdown on intravitreal therapy outcomes: Fight Retinal Blindness registry

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry

Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry

Characterization of poor visual outcomes of diabetic macular edema: the Fight Retinal Blindness! Project

Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry

Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration

Follow us

Quick links